{"brief_title": "Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.", "brief_summary": "To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.", "detailed_description": "Patients are randomized to receive azithromycin orally or intravenously, with crossover to the alternate treatment after a 21-day wash-out period.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Azithromycin", "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Antiretroviral agents, provided regimen has been stable for at least 1 month. Patients must have: - HIV infection. - CD4 count <= 200 cells/mm3. - No active opportunistic infection (pending discussion with Pfizer Clinician). Prior Medication: Allowed: - Prior antiretroviral agents. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Active intercurrent illness (pending discussion with the Pfizer Clinician). - Allergies to macrolide antibiotics. - Signs and symptoms of severe illness that would preclude treatment. Patients with the following prior conditions are excluded: - History of clinically significant allergic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease. - Clinically important change in baseline status within 4 weeks prior to study entry. - Condition affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies) within 4 weeks prior to study entry. Prior Medication: Excluded: - Investigational drugs including treatment IND drugs within 4 weeks prior to study entry. Known drug or alcohol dependence.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00002139.xml"}